Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease

Siddharth Singh, Darrell S. Pardi

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.

Original languageEnglish (US)
Pages (from-to)457-478
Number of pages22
JournalGastroenterology Clinics of North America
Issue number3
StatePublished - Sep 2014


  • Adalimumab
  • Anti-tumor necrosis factor
  • Certolizumab pegol
  • Crohn disease
  • Infliximab

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease'. Together they form a unique fingerprint.

Cite this